Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 165 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer... March 31, 2025 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... May 19, 2021 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers January 21, 2022 Load more HOT NEWS Tattoo Artist Helps Breast Cancer Survivors Cover Their Port Scars Can I Have a Non-Violent Relationship with Cancer (Part 2) New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma 11 Sun Safety Myths Debunked
